Evidence map›Paper›PMID 28752050›Full record

ArticleMolecular metabolism2017

Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.

Zhimin Chen, Guo-Xiao Wang, Sara L Ma, Dae Young Jung, Hyekyung Ha, Tariq Altamimi, Xu-Yun Zhao, Liang Guo, Peng Zhang, Chun-Rui Hu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Expression and significance of ependymin-related protein 1 and neuregulin 4 in the serum of patients with polycystic ovary syndrome.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Inflammation in MASLD progression and cancer.JHEP reports : innovation in hepatology · 2025
    Review
  19. Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Zhimin ChenLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Guo-Xiao WangLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Sara L MaLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Dae Young JungProgram in Molecular Medicine and Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Hyekyung HaProgram in Molecular Medicine and Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Tariq Altamimi423 Heritage Medical Research Building, University of Alberta Edmonton, Alberta T6G 2S2, Canada.
Xu-Yun ZhaoLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Liang GuoLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Peng ZhangLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Chun-Rui HuWeldon School of Biomedical Engineering and Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
Ji-Xin ChengWeldon School of Biomedical Engineering and Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
Gary D Lopaschuk423 Heritage Medical Research Building, University of Alberta Edmonton, Alberta T6G 2S2, Canada.
Jason K KimProgram in Molecular Medicine and Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jiandie D LinLife Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA. Electronic address: jdlin@umich.edu.
University of Michigan–Ann Arbor · USUniversity of Massachusetts Chan Medical School · USPurdue University West Lafayette · USUniversity of Alberta · CA

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Scott Soleimanpour · 2013 to 2026
$24.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joyce Lee · 2010 to 2026
$20.3M
Metabolic crosstalk through brown fat-enriched secreted factorsR01DK102456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiandie D Lin · 2015 to 2026
$4.9M
UMass Mouse Metabolic Phenotyping Center - Metabolism CoreU2CDK093000 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIM, JASON K · 2016 to 2021
$4.6M
Endocrine regulation of metabolic health during agingR21AG055379 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIN, JIANDIE D · 2017 to 2018
$426k
Long noncoding RNA regulation of hepatic lipogenesis and NAFLDK99DK106664 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHAO, XUYUN · 2016 to 2017
$178k
NIA NIH HHS R21 AG055379NIDDK NIH HHS K99 DK106664NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK102456NIDDK NIH HHS U2C DK093000
6 · The paper itself

Abstract

objectiveBrown and white adipose tissue exerts pleiotropic effects on systemic energy metabolism in part by releasing endocrine factors. Neuregulin 4 (Nrg4) was recently identified as a brown fat-enriched secreted factor that ameliorates diet-induced metabolic disorders, including insulin resistance and hepatic steatosis. However, the physiological mechanisms through which Nrg4 regulates energy balance and glucose and lipid metabolism remain incompletely understood. The aims of the current study were: i) to investigate the regulation of adipose Nrg4 expression during obesity and the physiological signals involved, ii) to elucidate the mechanisms underlying Nrg4 regulation of energy balance and glucose and lipid metabolism, and iii) to explore whether Nrg4 regulates adipose tissue secretome gene expression and adipokine secretion.

methodsWe examined the correlation of adipose Nrg4 expression with obesity in a cohort of diet-induced obese mice and investigated the upstream signals that regulate Nrg4 expression. We performed metabolic cage and hyperinsulinemic-euglycemic clamp studies in Nrg4 transgenic mice to dissect the metabolic pathways regulated by Nrg4. We investigated how Nrg4 regulates hepatic lipid metabolism in the fasting state and explored the effects of Nrg4 on adipose tissue gene expression, particularly those encoding secreted factors.

resultsAdipose Nrg4 expression is inversely correlated with adiposity and regulated by pro-inflammatory and anti-inflammatory signaling. Transgenic expression of Nrg4 increases energy expenditure and augments whole body glucose metabolism. Nrg4 protects mice from diet-induced hepatic steatosis in part through activation of hepatic fatty acid oxidation and ketogenesis. Finally, Nrg4 promotes a healthy adipokine profile during obesity.

conclusionsNrg4 exerts pleiotropic beneficial effects on energy balance and glucose and lipid metabolism to ameliorate obesity-associated metabolic disorders. Biologic therapeutics based on Nrg4 may improve both type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) in patients.

Indexed as

AdipocytesAdipokinesAnimalsCells, CulturedDiet, High-FatEnergy MetabolismFatty AcidsGlucoseLiverMiceMice, Inbred C57BLNeuregulinsNon-alcoholic Fatty Liver DiseaseObesityAdipokinesFatty AcidsGlucoseneuregulin-4NeuregulinsAdipokineAdipose tissueBAT, Brown adipose tissueBMPs, Bone morphogenetic proteinsBrown fatCoA, Co-enzyme ADiabeteseWAT, epididymal WATFGF21, Fibroblast growth factor 21GPR120, G-protein coupled receptor 120HFD, High-fat dietIL-6, Interleukin-6KO, KnockoutNAFLDNALFD, Non-alcoholic fatty liver diseaseNrg4Nrg4, Neuregulin 4TAG, TriglycerideTg, TransgenicTNFα, Tumor necrosis factor αUCP-1, Uncoupling protein 1VEGFα, Vascular endothelial growth factor αWAT, White adipose tissueWT, Wild type

Identifiers

PMID28752050
PMCPMC5518721
OpenAlexW2721080306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.